Lab
Lab Works, LLC
Lab Works, LLC was paid $41.64M by Medicaid between Mar 2019 and Nov 2024, across 128 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 29% of everything it billed.
33Billing provider infoLAB WORKS, LLC
HOMEWOOD, AL 35209
HOMEWOOD, AL 35209
33aNPI1861900698assigned 01/15/2018
33bProvider typeClinical Medical Laboratory
28Total paid$41.64M
24GClaims912,295
24DCodes billed128
24AFirst – last monthMar 2019 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Alabama
Rank by total paid#5 of 61
Median peer was paid$46K
This provider vs. median914×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 550 | $31K | |
| 2020 | 36,834 | $2.23M | |
| 2021 | 172,792 | $8.29M | |
| 2022 | 280,335 | $12.27M | |
| 2023 | 246,560 | $11.05M | |
| 2024incomplete | 175,224 | $7.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 29% | 65,032 | 55,002 | $11.94M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 21% | 61,132 | 51,780 | $8.54M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 10.0% | 84,982 | 78,801 | $4.15M |
| 87634 | 4.5% | 46,048 | 42,304 | $1.89M | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.3% | 45,630 | 38,247 | $1.78M |
| 87581 | 3.1% | 54,313 | 44,679 | $1.27M | |
| 87486 | 3.0% | 53,978 | 44,425 | $1.27M | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.0% | 32,517 | 31,195 | $1.26M |
| 87541 | 2.4% | 41,793 | 39,336 | $1.02M | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.4% | 61,994 | 57,493 | $993K |
| 87496 | 2.0% | 33,289 | 31,559 | $822K | |
| 87532 | 2.0% | 33,288 | 31,558 | $822K |
116 more codes
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 46,185 | $689K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 25,368 | $622K |
| 87481 | 1.5% | 10,700 | $618K | |
| 87640 | 1.2% | 27,430 | $520K | |
| 87653 | 1.0% | 21,707 | $420K | |
| 87631 | <1% | 6,138 | $363K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 2,867 | $351K |
| 87529 | <1% | 6,059 | $243K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,021 | $183K |
| 87070 | <1% | 21,320 | $169K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,146 | $168K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,675 | $151K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,413 | $146K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,394 | $106K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,316 | $103K |
| 87511 | <1% | 4,525 | $103K | |
| 87507 | <1% | 518 | $102K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 801 | $73K |
| 80053 | Comprehensive metabolic panel | <1% | 7,467 | $73K |
| 87641 | <1% | 3,730 | $68K | |
| 80061 | Lipid panel | <1% | 5,166 | $62K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,651 | $59K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,789 | $49K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,704 | $40K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,957 | $32K |
| 84439 | <1% | 3,808 | $29K | |
| 82607 | <1% | 1,319 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,591 | $18K |
| 80055 | <1% | 396 | $18K | |
| 82728 | <1% | 1,563 | $17K | |
| 87500 | <1% | 833 | $16K | |
| 87493 | <1% | 765 | $15K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 201 | $13K |
| 83655 | <1% | 1,147 | $13K | |
| 84480 | <1% | 813 | $12K | |
| 87077 | <1% | 1,604 | $12K | |
| 84481 | <1% | 866 | $11K | |
| 86780 | <1% | 1,016 | $11K | |
| 83540 | <1% | 1,800 | $11K | |
| 83525 | <1% | 984 | $10K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,057 | $8K |
| 84466 | <1% | 605 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 404 | $7K |
| 86003 | <1% | 105 | $7K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 379 | $6K |
| 86140 | <1% | 1,325 | $6K | |
| 87088 | <1% | 609 | $5K | |
| 83020 | <1% | 405 | $4K | |
| 87498 | <1% | 239 | $4K | |
| 83550 | <1% | 876 | $4K | |
| 87184 | <1% | 684 | $4K | |
| 88142 | <1% | 226 | $4K | |
| 82105 | <1% | 269 | $4K | |
| 86850 | <1% | 953 | $4K | |
| 85027 | <1% | 771 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 69 | $3K |
| 86665 | <1% | 81 | $3K | |
| 87081 | <1% | 412 | $3K | |
| 85652 | <1% | 1,092 | $3K | |
| 82677 | <1% | 130 | $3K | |
| 84702 | <1% | 266 | $3K | |
| 86038 | <1% | 185 | $2K | |
| 82746 | <1% | 258 | $2K | |
| 84403 | <1% | 120 | $2K | |
| 86703 | <1% | 170 | $2K | |
| 87563 | <1% | 1,364 | $2K | |
| 83735 | <1% | 410 | $2K | |
| 87340 | <1% | 446 | $2K | |
| 84681 | <1% | 147 | $2K | |
| 86336 | <1% | 130 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 68 | $2K |
| 85045 | <1% | 420 | $2K | |
| 83001 | <1% | 99 | $1K | |
| 82947 | <1% | 488 | $1K | |
| 86592 | <1% | 343 | $1K | |
| 86664 | <1% | 76 | $1K | |
| 86762 | <1% | 102 | $1K | |
| 85007 | <1% | 290 | $1K | |
| 86663 | <1% | 76 | $1K | |
| 87503 | <1% | 6,412 | $1K | |
| 86376 | <1% | 103 | $922.37 | |
| 82670 | <1% | 62 | $846.35 | |
| 86803 | <1% | 81 | $846.00 | |
| 85014 | <1% | 301 | $797.45 | |
| 87205 | <1% | 178 | $767.19 | |
| 81001 | <1% | 213 | $585.96 | |
| 84146 | <1% | 25 | $552.00 | |
| 82626 | <1% | 53 | $550.02 | |
| 84144 | <1% | 56 | $505.18 | |
| 82043 | <1% | 90 | $440.86 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 68 | $436.11 |
| 80076 | <1% | 54 | $380.58 | |
| 86900 | <1% | 411 | $359.70 | |
| 86901 | <1% | 411 | $355.21 | |
| 82533 | <1% | 51 | $351.64 | |
| 85046 | <1% | 78 | $348.08 | |
| 83003 | <1% | 49 | $337.32 | |
| 84432 | <1% | 48 | $336.00 | |
| 82570 | <1% | 48 | $276.00 | |
| 81511 | <1% | 29 | $230.00 | |
| 83002 | <1% | 12 | $225.56 | |
| 82785 | <1% | 31 | $204.40 | |
| 87186 | <1% | 21 | $185.54 | |
| 86141 | <1% | 16 | $156.00 | |
| 86431 | <1% | 32 | $153.62 | |
| 81003 | <1% | 67 | $149.01 | |
| 83021 | <1% | 14 | $125.36 | |
| 85018 | <1% | 26 | $64.00 | |
| 84550 | <1% | 13 | $48.00 | |
| 81005 | <1% | 21 | $41.64 | |
| 85004 | <1% | 60 | $4.45 | |
| 87501 | 0% | 53 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 28 | $0.00 |
| 85008 | 0% | 61 | $0.00 | |
| 85032 | 0% | 108 | $0.00 | |
| 86593 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEARL, ADAM (MANAGING PARTNER)